UbiQancer 2027 will bring together leading international researchers and early-career scientists working at the forefront of cancer-related ubiquitin biology and therapeutic innovation.
As the ubiquitin system is increasingly recognized as a rich source of cancer vulnerabilities and therapeutic opportunities, UbiQancer 2027 will showcase the latest advances shaping this rapidly evolving field. Topics will range from ubiquitin-dependent mechanisms of tumor development and therapy resistance to innovative therapeutic approaches, including targeted protein degradation technologies such as PROTACs and molecular glues for tackling previously undruggable cancer targets.
Organized by CRC/TRR 387 UbiQancer, the conference will connect researchers from molecular and structural biology, chemical biology, medicinal chemistry, pathology, and clinical oncology to foster interdisciplinary exchange and spark new collaborations across the cancer and ubiquitin research communities.
The scientific program will feature keynote lectures, invited talks by internationally recognized experts, selected short talks, poster presentations, and networking opportunities.
